Mineralys therapeutics has raised $192M in its IPO

 

Mineralys therapeutics has raised $192M in its IPO to develop therapies for diseases caused by elevated aldosterone, such as hypertension.  The company is listed on the Nasdaq Global Select Market at $16 per share. The company is developing Lorundrostat, an orally administered therapy that the company believes could help patients with uncontrolled hypertension. According to studies, elevated aldosterone production is prevalent in over 25% of all hypertensive patients. Elevated aldosterone levels drive blood volume and blood pressure up, leading to a higher risk of stroke, kidney damage, and heart failure. Mineralys is backed by investors such as RA Capital Management, Andera Partners, RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysios Capital, HealthCor Management, and Boulder Ventures.